The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

被引：3
|
作者：
Duan, Minghui [1 ]
Ma, Lan [2 ]
Wu, Qiuling [3 ]
Liang, Hong [4 ]
Wang, Wei [5 ]
Wu, Shaoling [5 ]
Mu, Lijun [6 ]
Lin, Hai [7 ]
Zhou, Hebing [8 ]
Shi, Hong-Xia [9 ]
Wang, Jinghua [10 ]
Jing, Hongmei [2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China
[2] Peking Univ Third Hosp, Beijing, Peoples R China
[3] Huazhong Univ Sci & Technol, Inst Hematol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Haerbin, Peoples R China
[5] Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao, Peoples R China
[6] Dalian Med Univ, Hosp 2, Dalian, Peoples R China
[7] First Hosp Jilin Univ, Dept Hematol, Jilin, Jilin, Peoples R China
[8] Capital Med Univ, Beijing Luhe Hosp, Dept Hematol, Beijing, Peoples R China
[9] Peking Univ, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol,Peoples Hosp, Beijing, Peoples R China
[10] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-188037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning
    Ali, Haris
    Snyder, David
    Stiller, Tracy
    Synold, Timothy
    Mokhtari, Saloomeh
    Palmer, Joycelynne
    Salhotra, Amandeep
    Pullarkat, Vinod A.
    Cai, Ji-lian
    Forman, Stephen J.
    Mei, Matthew
    Nakamura, Ryotaro
    BLOOD, 2019, 134
  • [32] Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study
    Jin, Jie
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Zhou, Hu
    Gao, Sujun
    Wang, Wei
    Dang, Huibing
    Chen, Yuqing
    Wang, Jishi
    Zhao, Peng
    Yang, Haiping
    Ma, Liangming
    Zhao, Qingwei
    Suo, Shanshan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE-1-RISK MYELOFIBROSIS (MF) FROM AN OPEN-LABEL, MULTICENTER, SINGLE-ARM EXPANDED-ACCESS STUDY
    Giraldo, P.
    Palandri, F.
    Palumbo, G. A.
    Zaritskey, A.
    Calistri, E.
    Skotnicki, A.
    Devos, T.
    Saavedra, D.
    Griesshammer, M.
    Al-Ali, H. K.
    Tavares, R.
    Vannucchi, A. M.
    Gupta, V.
    Raanani, P.
    Tannir, B.
    Ghosh, J.
    Ronco, J. Perez
    Foltz, L.
    HAEMATOLOGICA, 2015, 100 : 265 - 265
  • [34] Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
    Harrison, Claire N.
    Vannucchi, Alessandro M.
    Platzbecker, Uwe
    Cervantes, Francisco
    Gupta, Vikas
    Lavie, David
    Passamonti, Francesco
    Winton, Elliott F.
    Dong, Hua
    Kawashima, Jun
    Maltzman, Julia D.
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    LANCET HAEMATOLOGY, 2018, 5 (02): : E73 - E81
  • [35] A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
    Dilley, Kimberley
    Harb, Jason
    Jalaluddin, Muhammad
    Hutti, Jessica E.
    Potluri, Jalaja
    BLOOD, 2020, 136
  • [36] HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)
    Durrant, Simon
    Koren-Michowitz, Maya
    Lavie, David
    Martinez-Lopez, Joaquin
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    Stalbovskaya, Viktoriya
    Atienza, Edric
    Iommazzo, Dana
    Gopalakrishna, Prashanth
    Gisslinger, Heinz
    BLOOD, 2014, 124 (21)
  • [37] Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
    Yacoub, Abdulraheem
    Borate, Uma
    Rampal, Raajit K.
    Ali, Haris
    Wang, Eunice
    Gerds, Aaron T.
    Hobbs, Gabriela S.
    Kremyanskaya, Marina
    Winton, Elliott
    O'Connell, Casey
    Goel, Swati
    Oh, Stephen T.
    Schiller, Gary J.
    Assad, Albert
    Erickson-Viitanen, Sue
    Zhou, Feng
    Daver, Naval
    BLOOD, 2022, 140
  • [38] A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
    Gotlib, Jason
    Gabrail, Nashat
    O'Connell, Casey L.
    Garcia-Delgado, Regina
    Sbardellati, Timothy
    Rothbaum, Wayne M.
    McGreivy, Jesse
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    BLOOD, 2019, 134
  • [39] A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort
    Tavares, Renato
    Souza, Carmino Antonio De
    Paley, Carole
    Bouard, Catherine
    Tiwar, Ranjan
    Pasquini, Ricardo
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (01) : 46 - 53
  • [40] Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
    Gupta, Vikas
    Wolleschak, Denise
    Hasselbalch, Hans
    Vannucchi, Alessandro Maria
    Koschmieder, Steffen
    Cervantes, Francisco
    Li, Yang
    Dong, Tuochuan
    Wroclawska, Monika
    Bharathy, Savita
    Harrison, Claire
    BLOOD ADVANCES, 2020, 4 (13) : 3063 - 3071
12345